Mirtazapine for Chronic Insomnia in Older Adults
Key facts
- Who runs it
- Centre hospitalier de l'Université de Montréal (CHUM)
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 60 people enrolled
- Started
- 1 Oct 2022
- Ended
- 30 Jul 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Mirtazapine 7.5 MG Oral Tablet once daily at bedtime
- Placebo oral tablet once daily at bedtime
- Record updated
- 12 August 2024
Who can take part
- Age
- 65 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age 65 years and older
- A report of sleep initiation or maintenance problems
- An adequate opportunity and circumstances to sleep,
- To have at least one daytime consequence in relation to sleep complaint
- Sleep disorder and daytime consequences occur at least 3 times a week
- Duration of sleep disorder and daytime consequences for at least 3 months
- Sleep complaint cannot be explained by a sleep disorder other than chronic insomnia
Who cannot take part
- Use of drug for insomnia
- Cognitive Behavioural Therapy for insomnia
- Active psychiatric illness
- Parkinson's disease
- Major Neurocognitive disorders
- Contrindication to mirtazapine
- Use of Melatonin
- More than one fall in the last 3 months
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Insomnia is highly prevalent in the older adult population. The pharmacolgical management of chronic insomnia includes benzodiazepines and Z-drugs (zolpidem, zopiclone). Although these drugs are indicated for insomnia, they are not without side effects. These drugs are associated with cognitive impairment, rebound insomnia, falls and addiction. Mirtazapine has a hypnotic and sedative effect related to the blocking of histamine-1 receptors. No clinical trials has evaluated the efficacy and safety of mirtazapine for insomnia in the older population.
Read full original descriptionShow less
The goal of the study is to assess the efficacy and safety of mirtazapine compared to a placebo in older adults with chronic insomnia.
This prospective double-blind placebo controlled trial will be conducted in adults 65 years and older with chronic insomnia. The treatment group will receive mirtazapine 7.5 mg at bedtime for 28 days and the control group will receive a matching placebo for 28 days. The sample size for the pilot study will be 60 subjects, 30 subjects in the treatment group and 30 subjects in the control group. The efficacy of mirtazapine will be measured using the Insomnia Severity Index and the Pittsburgh Sleep Quality Index. Safety will be monitored during the study
The 2 groups in the trial
- TreatmentTreatment being tested
Mirtazapine 7.5 mg
Treatment: Mirtazapine 7.5 MG Oral Tablet once daily at bedtime
- ControlPlacebo, for comparison
Matching placebo
Treatment: Placebo oral tablet once daily at bedtime
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety and Efficacy of Mirtazapine in the Treatment of Chronic Insomnia in Older Adults : The MIRAGE Study
- Publications
- Record updated
- 12 August 2024